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SEVERAL issues pertinent to the valida-
tionofscreening testsand to theevaluation
of screening programmes have evolved,
largely in the epidemiological and general
medical literature (Vecchio, 1966; Holland,
1974; Henderson, 1976). For this reason,
laboratory scientists interested in the
development and validation of carcinogen
screening tests may not be fully aware of
some useful concepts. The paper reviews
several such concepts and their relation-
ships. These relationships explain, for
example, why the "predictive value",
although frequently used as an index of
the utility of a screening test, is not well
suited for that purpose.
A carcinogen screening test is usually
evaluated by applying it to a group of
substances, each of which is considered to
be, or not to be, a carcinogen according
to some selected criteria (i.e. animal
or human carcinogenesis). The specific
criteria chosen are beyond the scope of
this discussion; however, the validity
measures of a screening test are meaning-
ful only in the context of these criteria.
After some number, N, of substances has
been tested, the results may be described
using the format ofthe Table. (Terms used
to describe screening tests and screening
programmes are defined below the Table.)
A screening test is expected to designate
carcinogens as "positive" and to designate
non-carcinogens as "negative". Each of
these 2 distinct functions has its own
measure of validity. The proportion of
carcinogens which give a positive result in
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the test is termed the sensitivity. The
proportion of non-carcinogens which give
a negative result is termed the specificity
(MacMahon & Pugh, 1970). The sensitivity
and the specificity fully describe the
validity of a screening test.
To appreciate the meaning ofthe predic-
tive value, PV (the proportion of carcino-
gens among the substances which are
positive to the test) it is necessary to
change the frame ofreference from that of
a screening test to that of a screening pro-
gramme. By a screening programme we
mean the application of a screening test,
or a battery of such tests, to a specified
group of substances. PV can be inter-
preted only in the context of a screening
programme because it simultaneously
TABLE.-Terms used to describe screening
tests and screening programmes
Carcinogen*
Test
outcome Yes No Total
Positive
Negative
Total
a b a+b
c d c+d
a+c b+d N=a+b+c+d
Term
Sensitivity
Specificity
Predictive value
Prevalence
False positive proportion ("rate")
Falsenegative proportion ("rate")
Definitiont
a/(a+c)
d/(b+d)
a/(a+b)
(a+c)/N
b/(b+d)t
c/(a+c)t
* As defined by selected criteria.
t Usually each term is multiplied by 100 and
expressed as a percentage.
t Sometimes wrongly taken as b/(a+b) and
c/(c+d) respectively.J. A. COOPER II, R. SARACCI, P. COLE
reflects 3 things: the sensitivity and specifi-
ficity of the test being used and the pre-
valence (proportion) of carcinogens among
the substances tested. As the prevalence
changes so does the PV of a programme,
even though the sensitivity and specificity
of the test are constant.
The dependence of the PV on the pre-
valence can be illustrated by an example
based on a widely used screening test
(McCann & Ames, 1976). The test correctly
classified 157/175 substances considered
to be carcinogens and 94/108 non-carcino-
gens; that is, the test had a sensitivity of
900o and a specificity of 87%. The pre-
valence of carcinogens among this group
of substances was 62% (175/(175+108))
and, under this condition the PV is 92%.
However, assuming a constant sensitivity
and specificity, if the prevalence (propor-
tion) ofcarcinogens among the compounds
tested had been only 10%, the PV would
have been 44%o and, if the prevalence had
been only I%, the PV would have been
only 7°%.
The relationship between prevalence
and PV is strong (Figure). Even a highly
specific and sensitive test, A, is associated
with a PV of less than 90°%, until the
prevalence reaches 33%. And Test C, with
a low specificity, 80%, will be associated
with a PV of less than 9000 until the pre-
valence exceeds 7500. This strong depen-
dence of PV on prevalence suffices to
exclude it as ameasure oftestperformance.
However, PV has another important
limitation. For any prevalence less than
about 80%, PV is much more dependent
on the test's specificity than on its sensi-
tivity (Figure). This can be seen by con-
trasting the slight reduction in PV when
moving from Test A to Test B (reduced
sensitivity, constant specificity) with the
major reduction when moving from Test A
to Test C (constant sensitivity, reduced
specificity). Furthermore, the dependence
of PV on the specificity becomes stronger
as the prevalence declines. The reason for
this is easy to comprehend: as the objects
of the screen, carcinogens, become rarer
they are outnumbered to an increasing
C)
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FIGURE. Predictive value as a function of preval-
ence for hypothetical tests.
A. ( ) Sensitivity: 95O9, Specificity: 95%O.
B. ( ) Sensitivity: 80%, Specificity: 95%.
C. (---) Sensitivity: 95% Specificity: 80%.
extent by the many non-carcinogens
falsely classified as positive by a non-
specific test. This high dependence of PV
on specificity and its relative stability in
the presence of varying sensitivity should
be viewed as a serious limitation, especially
in a carcinogen screening test. For most
applications such a test should have a
high sensitivity, since the penalty asso-
ciated with "missing" a carcinogen is
likely to be much higher than that
associated with misclassifying a non-
carcinogen.
If PV is not a useful measure of the
validity of screening tests, how should
such tests be described? Several indices
for rating tests have been proposed, of
which Youden's J index is probably the
best known (Youden, 1950). It is the sum
ofthe sensitivity and the specificity, minus
unity. Youden pointed to several strengths
of his index, but it has been criticized on
several grounds (Greenhouse & Cornfield,
1950). It was pointed out that the sensi-
tivity and specificity of any test will
change (in inverse directions) as the
criterion of a "positive" test outcome
changes. That is, as the criterion of
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positivity is made more stringent, sensi-
tivity is reduced (some previously detect-
able carcinogens will be missed) but
specificity is increased (a non-carcinogen
is less likely to appear positive). Similarly,
if the criterion of positivity is relaxed,
sensitivity is improved but specificity is
reduced. In either case, the index may
remain unchanged, rise or fall, depending
on the extent of change in each of the 2
basic measures. It was also pointed out
that the J index is influenced equally by
sensitivity and specificity, a property
generally considered undesirable. (This
limitation could be overcome readily by
some type of weighting procedure.) To
these limitations of the J index we would
add a third, namely, that any single index
of test validity necessarily suppresses
valuable information on sensitivity and
specificity.
Our suggestion then, is simply that the
validation of a screening test be described
by presenting the 2 basic measures,
sensitivity and specificity. As there are
only 2, there seems little purpose in
developing a single index which must be
limited, to a greater or lesser extent, by
one or more of the 3 difficulties
mentioned.
While sensitivity and specificity fully
describe the validity of a test, 2 addi-
tional items of information are necessary
for their meaningful interpretation.
The first is the identity ofthe substances
used to evaluate the test. This is important
since, for most tests, there is no necessary
reason why the same performance should
be expected for substances of different
classes. There is in fact evidence (Purchase
et al., 1978) that tests may exhibit
different sensitivity and specificity when
applied to different classes of substances,
e.g. polycyclic hydrocarbons, alkylating
agents or aromatic amines.
The second is the criterion of a positive
test outcome since this, as already men-
tioned, directly influences both sensitivity
and specificity. When using any one test
an effort should be made to select the
optimum criterion of a positive outcome,
based on an assessment of the relative
penalties associated either with missing a
carcinogen or with erroneously implicating
a non-carcinogen as carcinogenic. Once
this criterion is established, improvement
can come about only by developing a
better test. Another alternative is to use
2 or more tests together or in sequence.
The first option, test development, is a
continuing process. The second is imme-
diately available and should always be
considered.
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